Literature DB >> 24924131

Luciferase-based reporter to monitor the transcriptional activity of the SIRT3 promoter.

F Kyle Satterstrom1, Marcia C Haigis2.   

Abstract

Sirtuin 3 (SIRT3) is a major regulator of oncometabolism. Indeed, the activity of SIRT3 significantly affects the response to oxidative stress, glycolytic proficiency, and tumorigenic potential of malignant cells. Thus, a system to accurately measure the transcriptional activity of the SIRT3 promoter could facilitate the identification of novel antineoplastic agents or have diagnostic applications. Here, we describe all the steps involved in the development of a luciferase-based reporter system to measure the activation of the human SIRT3 promoter, encompassing the design of appropriate primers, the cloning of the promoter fragment, and its site-directed mutagenesis. We validated this system in human embryonic kidney 293T cells, taking advantage of the renowned ability of the transcription factor estrogen-related receptor α to transactivate SIRT3. Moreover, here we demonstrate that SIRT3 expression is responsive to rapamycin, a small inhibitor of mammalian target of rapamycin that has been extensively employed as a caloric restriction mimetic. Finally, we provide an overview of the complementary molecular biology techniques that might be employed to further verify the reliability of this system.
© 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Caloric restriction mimetic; Luciferase-based reporter plasmid; Oncometabolism; Promoter analysis; Rapamycin; SIRT3

Mesh:

Substances:

Year:  2014        PMID: 24924131      PMCID: PMC5748892          DOI: 10.1016/B978-0-12-801329-8.00007-6

Source DB:  PubMed          Journal:  Methods Enzymol        ISSN: 0076-6879            Impact factor:   1.600


  21 in total

1.  Transcription factor binding and modified histones in human bidirectional promoters.

Authors:  Jane M Lin; Patrick J Collins; Nathan D Trinklein; Yutao Fu; Hualin Xi; Richard M Myers; Zhiping Weng
Journal:  Genome Res       Date:  2007-06       Impact factor: 9.043

Review 2.  Sirtuins as regulators of metabolism and healthspan.

Authors:  Riekelt H Houtkooper; Eija Pirinen; Johan Auwerx
Journal:  Nat Rev Mol Cell Biol       Date:  2012-03-07       Impact factor: 94.444

3.  Characterization of a bidirectional promoter shared between two human genes related to aging: SIRT3 and PSMD13.

Authors:  D Bellizzi; S Dato; P Cavalcante; G Covello; F Di Cianni; G Passarino; G Rose; G De Benedictis
Journal:  Genomics       Date:  2006-10-23       Impact factor: 5.736

4.  Sirt3 promotes the urea cycle and fatty acid oxidation during dietary restriction.

Authors:  William C Hallows; Wei Yu; Brian C Smith; Mark K Devries; Mark K Devires; James J Ellinger; Shinichi Someya; Michael R Shortreed; Tomas Prolla; John L Markley; Lloyd M Smith; Shimin Zhao; Kun-Liang Guan; John M Denu
Journal:  Mol Cell       Date:  2011-01-21       Impact factor: 17.970

5.  Characterization of PF-4708671, a novel and highly specific inhibitor of p70 ribosomal S6 kinase (S6K1).

Authors:  Laura R Pearce; Gordon R Alton; Daniel T Richter; John C Kath; Laura Lingardo; Justin Chapman; Catherine Hwang; Dario R Alessi
Journal:  Biochem J       Date:  2010-10-15       Impact factor: 3.857

6.  SIRT3 is a mitochondria-localized tumor suppressor required for maintenance of mitochondrial integrity and metabolism during stress.

Authors:  Hyun-Seok Kim; Krish Patel; Kristi Muldoon-Jacobs; Kheem S Bisht; Nukhet Aykin-Burns; J Daniel Pennington; Riet van der Meer; Phuongmai Nguyen; Jason Savage; Kjerstin M Owens; Athanassios Vassilopoulos; Ozkan Ozden; Seong-Hoon Park; Keshav K Singh; Sarki A Abdulkadir; Douglas R Spitz; Chu-Xia Deng; David Gius
Journal:  Cancer Cell       Date:  2010-01-19       Impact factor: 31.743

7.  SIRT3 regulates mitochondrial fatty-acid oxidation by reversible enzyme deacetylation.

Authors:  Matthew D Hirschey; Tadahiro Shimazu; Eric Goetzman; Enxuan Jing; Bjoern Schwer; David B Lombard; Carrie A Grueter; Charles Harris; Sudha Biddinger; Olga R Ilkayeva; Robert D Stevens; Yu Li; Asish K Saha; Neil B Ruderman; James R Bain; Christopher B Newgard; Robert V Farese; Frederick W Alt; C Ronald Kahn; Eric Verdin
Journal:  Nature       Date:  2010-03-04       Impact factor: 49.962

8.  Sirtuin 3, a new target of PGC-1alpha, plays an important role in the suppression of ROS and mitochondrial biogenesis.

Authors:  Xingxing Kong; Rui Wang; Yuan Xue; Xiaojun Liu; Huabing Zhang; Yong Chen; Fude Fang; Yongsheng Chang
Journal:  PLoS One       Date:  2010-07-22       Impact factor: 3.240

9.  An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1.

Authors:  Carson C Thoreen; Seong A Kang; Jae Won Chang; Qingsong Liu; Jianming Zhang; Yi Gao; Laurie J Reichling; Taebo Sim; David M Sabatini; Nathanael S Gray
Journal:  J Biol Chem       Date:  2009-01-15       Impact factor: 5.157

10.  The transcriptional coactivator PGC-1 regulates the expression and activity of the orphan nuclear receptor estrogen-related receptor alpha (ERRalpha).

Authors:  Sylvia N Schreiber; Darko Knutti; Kathrin Brogli; Thomas Uhlmann; Anastasia Kralli
Journal:  J Biol Chem       Date:  2003-01-08       Impact factor: 5.157

View more
  3 in total

1.  CDK1-Mediated SIRT3 Activation Enhances Mitochondrial Function and Tumor Radioresistance.

Authors:  Rui Liu; Ming Fan; Demet Candas; Lili Qin; Xiaodi Zhang; Angela Eldridge; June X Zou; Tieqiao Zhang; Shuaib Juma; Cuihong Jin; Robert F Li; Julian Perks; Lun-Quan Sun; Andrew T M Vaughan; Chun-Xu Hai; David R Gius; Jian Jian Li
Journal:  Mol Cancer Ther       Date:  2015-07-03       Impact factor: 6.261

2.  Nuclear respiratory factor 2 induces SIRT3 expression.

Authors:  F Kyle Satterstrom; William R Swindell; Gaëlle Laurent; Sejal Vyas; Martha L Bulyk; Marcia C Haigis
Journal:  Aging Cell       Date:  2015-06-24       Impact factor: 9.304

3.  Comparison of Sirtuin 3 Levels in ALS and Huntington's Disease-Differential Effects in Human Tissue Samples vs. Transgenic Mouse Models.

Authors:  Eva Buck; Hanna Bayer; Katrin S Lindenberg; Johannes Hanselmann; Noemi Pasquarelli; Albert C Ludolph; Patrick Weydt; Anke Witting
Journal:  Front Mol Neurosci       Date:  2017-05-26       Impact factor: 5.639

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.